Paul Armstrong, MD
November 16th, 2010
Putting the EMPHASIS on Eplerenone for HF
Paul Armstrong, MD
In the EMPHASIS-HF study, aldosterone inhibition with eplerenone reduced the rate of death from cardiovascular causes or heart-failure (HF) hospitalizations by about 37% (compared with placebo) in patients with functional NHYA class II HF. CardioExchange welcomes Paul Armstrong, Professor of Medicine in the Division of Cardiology at the University of Alberta, to answer our questions […]
November 14th, 2010
AHA: A Global View
Paul Armstrong, MD
Several Cardiology Fellows who are attending this week’s AHA meeting are blogging together on CardioExchange. The Fellows include Susan Cheng, Madhavi Reddy, John Ryan, and Amit Shah. Check back often to learn about the biggest buzz in Chicago this week — whether it’s a poster, a presentation, or the word in the hallways. You can read […]
NEJM Journal Watch — Recent Cardiology Articles- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?